On Tuesday, Definium Therapeutics Inc (NASDAQ: MNMD) was 7.13% up from the session before settling in for the closing price of $13.88. A 52-week range for MNMD has been $4.70 – $15.29.
During the last 5-year period, the sales growth of Healthcare Sector giant was 12.11%. When this article was written, the company’s average yearly earnings per share was at -30.32%. With a float of $73.44 million, this company’s outstanding shares have now reached $76.77 million.
Definium Therapeutics Inc (MNMD) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Definium Therapeutics Inc stocks. The insider ownership of Definium Therapeutics Inc is 2.80%, while institutional ownership is 51.92%. The most recent insider transaction that took place on Dec 26 ’25, was worth 73,623. In this transaction Chief Medical Officer of this company sold 5,600 shares at a rate of $13.15, taking the stock ownership to the 425,025 shares. Before that another transaction happened on Dec 26 ’25, when Company’s Chief Executive Officer sold 25,791 for $13.15, making the entire transaction worth $339,072. This insider now owns 778,477 shares in total.
Definium Therapeutics Inc (MNMD) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.41 earnings per share (EPS) during the time that was less than consensus figure (set at -0.28) by -0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.46 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.00% during the next five years compared to 12.11% growth over the previous five years of trading.
Definium Therapeutics Inc (NASDAQ: MNMD) Trading Performance Indicators
You can see what Definium Therapeutics Inc (MNMD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.97, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -1.75 in one year’s time.
